Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens

Table 5 Univariate and multivariate Cox proportional hazards regression analyses of the disease-free survival of patients in the training set

Variables	Univariate analysis		Multivariate analysis
	P value	HR (95%CI)	P value	HR (95%CI)
Age, years	0.012a	1.03 (1.01-1.05)	0.003b	1.04 (1.01-1.06)
Sex
Male	0.700	1.00 (reference)	-	-
Female		0.92 (0.61-1.40)		-
Sampling position
Colon	0.071	1.00 (reference)	0.030a	1.00 (reference)
Rectum		1.47 (0.97-2.22)		1.59 (1.05-2.41)
Stage
II	< 0.001c	1.00 (reference)	< 0.001c	1.00 (reference)
III		2.77 (1.64-4.69)		2.76 (1.63-4.68)
ATP-TCA
Sensitive	0.008b	1.00 (reference)	0.002b	1.00 (reference)
Resistant		3.92 (1.44-10.68)		4.98 (1.81-13.72)

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

HR: Hazard ratio; CI: Confidence interval; ATP-TCA: Adenosine triphosphate-based tumour chemotherapy sensitivity test.